India-born scientist spearheads Covid vaccine tests in animals

TV Jayan New Delhi | Updated on April 06, 2020 Published on April 06, 2020

File photo

An India-born virologist at Australian Centre for Disease Preparedness (ACDP) at Geelong, a port city southwest of Melbourne, is heading preclinical animal tests of Covid-19 vaccines.

SS Vasan, who leads the Dangerous Pathogens team at ACDP, which is a part of Australian national research agency, the Commonwealth Scientific and Industrial Research Organisation, is heading the team that will carry out animal studies on different vaccines against SARS-CoV2, which causes Covid-19 infection.

Animal models

A team led by Vasan, senior principal research consultant for Health and Biosecurity at CSIRO, had earlier shown that ferrets – the domesticated European polecats – could be used as animal models to test the efficacy of vaccines and therapies against SARS-CoV2. This is because ferrets share lung physiology similar to humans’ and can thus be infected by the deadly virus which has so far caused over 1.28 million cases and killed more than 70,000 people worldwide.

As of now, the team led by Vasan, who also holds an honorary chair in Health Sciences at the University of York in the UK, will test two candidate vaccines being developed with funding from The Coalition for Epidemic Preparedness Innovations (CEPI), a foundation that takes donations from philanthropic, and civil society organisations to support independent vaccine projects.

CEPI has so far extended funding to eight potential Covid-19 vaccines. One CEPI-funded vaccine, developed by a US firm called Moderna, entered human trials in March. Significantly, the vice-chair of CEPI is Gagandeep Kang, Executive Director of the Translational Health Science and Technology Institute at Faridabad.

2 vaccines on test

Among the two vaccines being tested on ferrets, one is a DNA vaccine, INO-4800, developed by the US-based pharma firm Inovio and Beijing Advaccine, and the other one is from an Oxford University team. While the Oxford vaccine is said to be intramuscular, Vasan’s team will be testing its efficacy as intranasal as well.

“This is because I want to find out if intranasal administration will confer mucosal immunity so the vaccine will be more protective with just a single dose,” Vasan told BusinessLine from Geelong.

Both these vaccines are scheduled to enter Phase-I clinical trials with healthy volunteers. “Looking at the urgency of the situation, vaccine developers are conducting animal studies simultaneously,” Vasan said.

Recently, the Australian government announced an additional $220 million to CSIRO bio-security research facility in Geelong so that the infrastructure can be beefed up to handle deadly viruses such as SARS-CoV2 and test potential vaccines. The preclinical research by Vasan's team is funded by a partnership between CSIRO and CEPI.

Published on April 06, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.